Maxcyte, Inc.
MXCT· Nasdaq
Released Aug 6, 2024, after the close
10-Q filed Aug 6, 2024, 37 days after period end · 0001558370-24-011120
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | — | — | $6.98M | — |
| Net Income | -$9.38M | -$10.51M | -$8.26M | -$4.42M |
| EPS Diluted |
Maxcyte, Inc. · CIK 1287098 · Engraved from SEC EDGAR
| -$0.09 |
| -$0.10 |
| -$0.08 |
| -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.